Comparison of the preventive painkiller effect of etoricoxib and celecoxib after M3M surgery: A randomized, double-masked clinical trial

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-520695-26-00

Acronym

COX2M3M

Enrollment

Registered

2025-01-22

Start date

Unknown

Completion date

Unknown

Last updated

2025-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative period after mandibular M3 removal

Brief summary

Based on literature data, it is anticipated that the patients in the etoricoxib group will experience a greater reduction in postoperative pain and discomfort compared to the control (placebo) group. This outcome is hypothesized based on the pharmacological properties of the drug.

Interventions

DRUGETORICOXIB

DRUGCELECOXIB

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Based on literature data, it is anticipated that the patients in the etoricoxib group will experience a greater reduction in postoperative pain and discomfort compared to the control (placebo) group. This outcome is hypothesized based on the pharmacological properties of the drug.	—

Countries

Hungary

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026